The DOI matches its Crossref record; 10 of the 11 references it cites were found in a registry or an index, and 1 are not checked yet.
Correlation of IL-31 serum levels with severity of atopic dermatitis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-31 is a prominent pruritogenic cytokine produced by infiltrating TH2 cells in AD and correlates with disease severity97,184,185.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [185]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,597
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C. A., Hammond, A. J., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S., Haugen, H. S., Maurer, M. F., Harder, B., Johnston, J. V., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,018
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Müller, A., Lauerma, A., Pivarcsi, A., Soto, H., Kemény, L. V., Alenius, H. T., Dieu‐Nosjean, M., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,000
Neis, M. M., Peters, B., Dreuw, A., Wenzel, J., Bieber, T. R. M., Mauch, C., Krieg, T., Stanzel, S. F., Heinrich, P. C., Merk, H. F., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.07.015 · Cited by 377
Bilsborough, J., Leung, D. Y. M., Maurer, M. F., Howell, M. D., Boguniewcz, M., Yao, L. Y., Storey, H., LeCiel, C., Harder, B., & Gross, J. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.046 · Cited by 368
Pathophysiology of pruritus in atopic dermatitis: an overview
Ständer, S., & Steinhoff, M. S. (2002) · Experimental Dermatology · doi:10.1034/j.1600-0625.2002.110102.x · Cited by 250
Self-citationInvolvement of IL‐31 on scratching behavior in NC/Nga mice with atopic‐like dermatitis
Takaoka, A., Arai, I., Sugimoto, M., Honma, Y., Futaki, N., Nakamura, A., & Nakaike, S. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00405.x · Cited by 152
Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis
Takaoka, A., Arai, I., Sugimoto, M., Yamaguchi, A., Tanaka, M., & Nakaike, S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.04.040 · Cited by 120
Boguniewicz, M., Schmid‐Grendelmeier, P., & Leung, D. Y. M. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.04.044 · Cited by 86
A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema
Schulz, F., Marenholz, I., Fölster‐Holst, R., Chen, C. I.-U., Sternjak, A., Baumgrass, R., Esparza-Gordillo, J., Grüber, C., Nickel, R. G., Schreiber, S., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.07.065 · Cited by 81
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 299
Past, present, and future for biologic intervention in atopic dermatitis
Howell, M. D., Parker, M. L., Mustelin, T., & Ranade, K. (2015) · Allergy · doi:10.1111/all.12632 · Cited by 51
Mast cell mediators of significance in clinical practice in mastocytosis
Butterfield, J. H., Ravi, A., & Pongdee, T. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.011 · Cited by 48
Immunological milieu in mycosis fungoides and S ézary syndrome
Miyagaki, T., & Sugaya, M. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12305 · Cited by 49
New and emerging targeted systemic therapies: a new era for atopic dermatitis
Lee, D. E., Clark, A. K., Tran, K. A., & Shi, V. Y. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1373736 · Cited by 48
“Additionally, AD lesions have increased IL-31 mRNA expression compared to normal controls, with increased IL-31 receptor A (IL-31RA) expression in keratinocytes and dermal nerve fibers (10,12).”
BackgroundInfluentialInvolvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions
Ruppenstein, A., Limberg, M. M., Loser, K., Kremer, A. E., Homey, B., & Raap, U. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.627985 · Cited by 48
“In this regard, IL-31 has been shown to correlate with disease severity and pruritus in AD patients (75).”
BackgroundSelf-citationThe evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
David, E., Ungar, B., Renert‐Yuval, Y., Facheris, P., DUCA, E. D., & Guttman‐Yassky, E. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14263 · Cited by 49
The histamine H4 receptor: Targeting inflammatory disorders
Walter, M., Kottke, T., & Stark, H. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.029 · Cited by 47
English version of clinical practice guidelines for the management of atopic dermatitis 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17544 · Cited by 54
Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis
Nakahara, T., Morimoto, H., Murakami, N., & Furue, M. (2017) · Pediatric Allergy and Immunology · doi:10.1111/pai.12842 · Cited by 46
McCandless, E. E., Rugg, C. A., Fici, G. J., Messamore, J. E., Aleo, M. M., & Gonzales, A. J. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.10.017 · Cited by 45
Biomarkers for Itch and Disease Severity in Atopic Dermatitis
Lee, C., & Yu, H. (2011) · Current problems in dermatology · doi:10.1159/000323307 · Cited by 45
Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments
Wong, L., Wu, T. C., & Lee, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071485 · Cited by 44
“The blood level of IL-31 is increased in many pruritic skin diseases including AD, cutaneous T cell lymphoma, uremic pruritus, chronic urticaria, and prurigo nodularis [37].”
BackgroundVakirlis, E., Lazaridou, E., Tzellos, T., Gerou, S., Chatzidimitriou, D., & Ioannides, D. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03800.x · Cited by 43
Lewis, K. E., Holdren, M. S., Maurer, M. F., Underwood, S., Meengs, B., Julien, S. H., Byrnes-Blake, K. A., Freeman, J. A., Bukowski, T., Wolf, A. C., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13794 · Cited by 42
Okano, M., Fujiwara, T., Higaki, T., Makihara, S., Haruna, T., Noda, Y., Kanai, K., Kariya, S., Yasueda, H., & Nishizaki, K. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.029 · Cited by 42
Kasraie, S., Niebuhr, M., & Werfel, T. (2013) · Allergy · doi:10.1111/all.12152 · Cited by 42
“Recently, we provided evidence that serum IL-31 levels were significantly higher in patients with AD and correlated with disease activity in AD (3).”
BackgroundSelf-citationMalek, M., Gleń, J., Rębała, K., Kowalczyk, A., Sobjanek, M., Nowicki, R. J., Rückemann-Dziurdzińska, K., & Sokołowska‐Wojdyło, M. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-1958 · Cited by 42
Current and Future Biomarkers in Atopic Dermatitis
Thijs, J. L., de Bruin-Weller, M. S., & Hijnen, D. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.008 · Cited by 42
“Several studies investigated correlations between serum IL-31 levels and disease severity.(50) However, the correlation of IL-31 with pruritus has not yet been investigated.”
BackgroundDupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
Eshtiaghi, P., & Gooderham, M. (2018) · Core evidence · doi:10.2147/ce.s133661 · Cited by 42
“IL-31 mediates pruritus and inflammation and has been correlated with disease severity.(28) In a Phase II trial, nemolizumab significantly improved pruritus as the primary outcome.”
Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update
Wang, D., & Beck, L. A. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0205-5 · Cited by 44
“It is released by activated Th cells (especially Th2), mast cells, and mononuclear cells and is thought to mediate itch in a number of conditions, including AD, prurigo nodularis, and cutaneous T-cell lymphoma [48, 67, 125].”
BackgroundThe interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma
Ferretti, E., Tripodo, C., Pagnan, G., Guarnotta, C., Marimpietri, D., Corrias, M. V., Ribatti, D., Zupo, S., Orcioni, G. F., Ravetti, J. L., et al. (2014) · Leukemia · doi:10.1038/leu.2014.291 · Cited by 41
Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms
Chaowattanapanit, S., Choonhakarn, C., Salao, K., Winaikosol, K., Julanon, N., Wongjirattikarn, R., Foocharoen, C., & Sompornrattanaphan, M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05621 · Cited by 40
Atopic Dermatitis Itch: Scratching for an Explanation
Soares, G. B., Hashimoto, T., & Yosipovitch, G. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.10.048 · Cited by 37
Advances in therapeutic strategies for the treatment of pruritus
Stull, C. M., Lavery, M. J., & Yosipovitch, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1127355 · Cited by 37
“In AD, serum levels of IL-31 are elevated and correlate with disease severity.[111]”
BackgroundTarget-oriented therapy: Emerging drugs for atopic dermatitis
Lauffer, F., & Ring, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1146681 · Cited by 36
“[41] Furthermore, IL-31 serum level correlates with AD disease score [43], although it is unclear whether IL31 contributes directly to AD development or if its production is a side effect of the inflammatory process.”
BackgroundClinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
Nedoszytko, B., Arock, M., Lyons, J. J., Bachelot, G., Schwartz, L. B., Reiter, A., Jawhar, M., Schwaab, J., Lange, M., Greiner, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010411 · Cited by 37
The Role of the Histamine H4 Receptor in Atopic Dermatitis
Mommert, S., Gschwandtner, M., Gutzmer, R., & Werfel, T. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0162-7 · Cited by 37
Self-citationExpression and function of histamine and its receptors in atopic dermatitis
Albrecht, M., & Dittrich, A. (2015) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-015-0027-1 · Cited by 36
“Moreover, histamine regulates the release of nerve growth factor [11] and semaphorin 3A from keratinocytes which also act as pruritic factors, and H1R targeting reduces IL-31, a pro-pruritic cytokine which additionally plays an important role in skin barrier integrity [12–14].”
BackgroundHuth, S., Schmitt, L., Marquardt, Y., Heise, R., Lüscher, B., Amann, P. M., & Baron, J. M. (2018) · Experimental Dermatology · doi:10.1111/exd.13697 · Cited by 38
Childhood atopic dermatitis: current developments, treatment approaches, and future expectations
Çetinkaya, P. G., & Şahiner, Ü. M. (2019) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1810-105 · Cited by 36
Biologics for chronic inflammatory skin diseases: an update for the clinician
Yao, Y., Jørgensen, A. R., & Thomsen, S. F. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1589643 · Cited by 35
The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases
Topal, F. A., Zuberbier, T., Makris, M. P., & Hofmann, M. A. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000658 · Cited by 37
“Noteworthy, serum IL-31 is elevated in both children and adults with atopic dermatitis [44,45] and it was proposed as a marker of atopic dermatitis severity and as biomarker [43].”
BackgroundKwon, H. I., Jeong, N. H., Jun, S. H., Son, J. H., Kim, S., Jeon, H., Kang, S. C., Kim, S. H., & Lee, J. C. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.04.027 · Cited by 36
Current novel approaches in systemic therapy of atopic dermatitis
Werfel, T., & Biedermann, T. (2015) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000199 · Cited by 34
“The expression of IL-31 is elevated in atopic dermatitis skin and serum levels of IL-31 correlate with disease severity in patients with atopic dermatitis [36,37].”
BackgroundSelf-citationThe Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis
Wong, L., Yen, Y.-T., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137227 · Cited by 35
“Additionally, a positive correlation between serum IL-31 levels and the severity of AD patients has been reported [101].”
BackgroundDai, X., Shiraishi, K., Muto, J., Utsunomiya, R., Mori, H., Murakami, M., & Sayama, K. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.05.033 · Cited by 34
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Trier, A. M., & Kim, B. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac016 · Cited by 32
Bonciani, D., Quintarelli, L., BIANCO, E. D., Bianchi, B., & Caproni, M. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.04.008 · Cited by 32
Park, B.-K., Park, Y., Jung, I. C., Kim, S., Choi, J. J., Do, M. H., Kim, S. Y., & Jin, M. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.02.040 · Cited by 31
“Indeed, skin biopsies of AD patients display increased IL-31 mRNA expression compared to normal skin, and increased serum levels of IL-31 are correlated with itching and AD severity in human (Raap et al., 2008).”
BackgroundIL-31 plays dual roles in lung inflammation in an OVA-induced murine asthma model
Huang, J., Yue, H., Jiang, T., Gao, J. Y., Shi, Y., Shi, B., Wu, X., & Gou, X. (2019) · Biology Open · doi:10.1242/bio.036244 · Cited by 29
“Studies carried out in mouse models as well as data obtained from the analysis of sera and biopsies from patients with atopic dermatitis (AD) indicate that IL-31 is involved in the pathogenesis of allergic skin inflammatory diseases and is upregulated in these diseases (Neis et al., 2006; SiniewiczLuzenczyk et al., 20…”
BackgroundKulczycka, L., Cynkier, A., Waszczykowska, E., Woźniacka, A. J., & Żebrowska, A. (2017) · BioMed Research International · doi:10.1155/2017/5965492 · Cited by 31
Lange, M., Gleń, J., Zabłotna, M., Nedoszytko, B., Sokołowska‐Wojdyło, M., Rębała, K., Ługowska-Umer, H., Niedoszytko, M., Górska, A., Sikorska, M., et al. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2474 · Cited by 30
Immunoinflammatory Biomarkers in Serum Are Associated with Disease Severity in Atopic Dermatitis
Holm, J. G., Hurault, G., Agner, T., Clausen, M., Kežić, S., Tanaka, R. J., & Thomsen, S. F. (2021) · Dermatology · doi:10.1159/000514503 · Cited by 30
IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses
Roh, Y. S., Choi, J., Sutaria, N. H., Belzberg, M., Kwatra, M. M., & Kwatra, S. G. (2021) · Drugs · doi:10.1007/s40265-021-01521-1 · Cited by 30
Immune mediators and therapies for pruritus in atopic dermatitis and psoriasis
Yu, S., Li, Y., Zhou, Y., Follansbee, T., & Hwang, S. T. (2019) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12049 · Cited by 28
Passive Sweat-Based Pruritic Cytokine Detection and Monitoring System
Upasham, S., Rice, P., Shahub, S., Dhamu, V. N., & Prasad, S. (2022) · ECS Sensors Plus · doi:10.1149/2754-2726/ac82bc · Cited by 28
“IL-31 levels correspond to the disease severity and are often correlated with SCORAD ranges.(26) This work evaluates the performance of the wearable sensor in four different simulated flare conditions.”
BackgroundIntractable Itch in Atopic Dermatitis: Causes and Treatments
Umehara, Y., Kiatsurayanon, C., Trujillo-Páez, J. V., Chieosilapatham, P., Peng, G., Yue, H., Nguyen, H. L. T., Song, P., Okumura, K., Ogawa, H., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030229 · Cited by 29
Molecular cloning of canine interleukin-31 and its expression in various tissues
Mizuno, T., Kanbayashi, S., OKAWA, T., Maeda, S., & Okuda, M. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2009.03.014 · Cited by 27
Simon, D., & Lang, K. K. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834cad0a · Cited by 26
Immunomodulating Agents as Antipruritics
Erickson, S. P., Nahmias, Z. P., Rosman, I. S., & Kim, B. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.014 · Cited by 27
Novel drugs for the treatment of chronic pruritus
Pereira, M. P., & Ständer, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1548606 · Cited by 26
“IL-31 has been identified as a key mediator for pruritus induction in inflammatory dermatoses [10].”
BackgroundInfluentialSelf-citationChe, D. N., Shin, J. Y., Kang, H. J., Cho, B. O., Kim, Y., & Jang, S. I. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106403 · Cited by 26
Siniewicz‐Luzeńczyk, K., Stańczyk-Przyłuska, A., & Zeman, K. (2013) · Advances in Dermatology and Allergology · doi:10.5114/pdia.2013.38356 · Cited by 26
“, as one of the first, achieved significantly higher serum IL-31 levels in the group of patients with AD [11].”
BackgroundFölster‐Holst, R., Papakonstantinou, E., Rüdrich, U., Buchner, M., Pité, H., Gehring, M., Kapp, A., Weidinger, S., & Raap, U. (2016) · Allergy · doi:10.1111/all.12916 · Cited by 26
“Previously, it was shown that IL-31 correlates with disease severity in adults and in children with atopic dermatitis (4, 5).”
BackgroundSelf-citationWerfel, T. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000477 · Cited by 26
Self-citationAtopic dermatitis and food allergy: More than sensitization
Davis, K. L., Claudio-Etienne, E., & Frischmeyer‐Guerrerio, P. A. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.06.005 · Cited by 31
Emerging drugs for the treatment of pruritus
Ständer, S., Weißhaar, E., & Raap, U. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051964 · Cited by 24
“In patients with AD, IL-31 serum levels correlate with disease severity and Th2 cytokines [14].”
BackgroundSelf-citationCutaneous neuroimmune crosstalk in pruritus
Agelopoulos, K., Pereira, M. P., Wiegmann, H., & Ständer, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.005 · Cited by 24
Self-citationThe Dawn of a New Era in Atopic Dermatitis Treatment
Yamamura, K., & Nakahara, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206145 · Cited by 24
Evolving Concepts in Atopic Dermatitis
Sidbury, R., & Khorsand, K. O. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0710-5 · Cited by 24
Rosine, N., Etcheto, A., Hendel, H., Séror, R., Briot, K., Moltó, A., Chanson, P., Taoufik, Y., Wendling, D., Lories, R. J. U., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25722-z · Cited by 23
The Future Antihistamines: Histamine H3 and H4 Receptor Ligands
Yu, F., Bonaventure, P., & Thurmond, R. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8056-4_12 · Cited by 23
IL-31 Is Overexpressed in Lichen Planus but Its Level Does Not Correlate with Pruritus Severity
Welz-Kubiak, K., Kobuszewska, A., & Reich, A. (2015) · Journal of Immunology Research · doi:10.1155/2015/854747 · Cited by 23
“Similar results have been presented by other authors [21, 22].”
ResultKanwal, S., Singh, S. K., Soman, S. P., Choudhury, S., Kumari, P., Ram, P. K., & Garg, S. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-90992-z · Cited by 23
Recent advances in pathophysiological mechanisms of itch
Tominaga, M., & Takamori, K. (2010) · Expert Review of Dermatology · doi:10.1586/edm.10.7 · Cited by 22
Analysis of Gene Expression in Atopic Dermatitis Using a Microabrasive Method
Bianchi, P., Ribet, V., Casas, C., Lejeune, O., Schmitt, A.-M., & Redoules, D. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.306 · Cited by 22
Otsuka, A., Honda, T., Doi, H., Miyachi, Y., & Kabashima, K. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10083.x · Cited by 21
Granzyme B in epithelial barrier dysfunction and related skin diseases
Jung, K., Pawluk, M. A., Lane, M. D., Nabai, L., & Granville, D. J. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00052.2022 · Cited by 22
IL-31 Associated with Coronary Artery Lesion Formation in Kawasaki Disease
Tseng, W.-N., Lo, M., Guo, M. M., Hsieh, K., Chang, W., & Kuo, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105195 · Cited by 20
“Blood IL-31 has been correlated to disease severity in atopic dermatitis [16] but had not been studied in KD to date.”
BackgroundNovel Therapeutic Approaches to Atopic Dermatitis
Osinka, K., Dumycz, K., Kwiek, B., & Feleszko, W. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0487-1 · Cited by 18
Nocchi, L., Roy, N., D’Attilia, M., Dhandapani, R., Maffei, M., Traista, A., Castaldi, L., Perlas, E., Chadick, C. H., & Heppenstall, P. A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0328-5 · Cited by 19
Current treatment strategies in refractory chronic pruritus
Pereira, M. P., Mittal, A. K., & Ständer, S. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.11.007 · Cited by 20
Self-citationEffect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
Roekevisch, E., Szegedi, K., Hack, D., Schram, M. E., Res, P. C. J. M., Bos, J. D., Leeflang, M., Luiten, R. M., Kežić, S., Spuls, P. I., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16164 · Cited by 19
Neuroimmune Circuits in Allergic Diseases
Cai, H., Zhu, X., & Sokol, C. L. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-032154 · Cited by 19
Therapy for pruritus in the elderly: a review of treatment developments
Pereira, M. P., & Ständer, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1444752 · Cited by 18
“Interleukin-31 plays an important role in the pathway of pruritic atopic dermatitis, being elevated in the serum of these patients [57].”
BackgroundSelf-citationKunimura, K., & Fukui, Y. (2021) · International Immunology · doi:10.1093/intimm/dxab065 · Cited by 17
“Recently, interleukin 31 (IL-31) has been shown to play a major role in AD-associated itch; for example, serum IL-31 levels were correlated with disease severity in AD patients (2, 3).”
BackgroundAltered plasma cytokines in dogs with atopic dermatitis
Mazrier, H., Vogelnest, L. J., Taylor, R. M., & Williamson, P. (2021) · Veterinary Dermatology · doi:10.1111/vde.13044 · Cited by 17
Increased IL-31 expression in serum and tissue protein in prurigo nodularis
Chaowattanapanit, S., Wongjirattikarn, R., Chaisuriya, N., Ungarreevittaya, P., Poosekeaw, P., Winaikosol, K., Choonhakarn, C., Julanon, N., & Salao, K. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221112561 · Cited by 17
Emerging Treatments and Novel Pathways in Pruritus
Morin, C. B., & Misery, L. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419852050 · Cited by 18
Sokołowska‐Wojdyło, M., Gleń, J., Zabłotna, M., Rębała, K., Trzeciak, M., Sikorska, M., Rückemann-Dziurdzińska, K., Nedoszytko, B., Florek, A. G., & Nowicki, R. J. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12666 · Cited by 17
Feld, M., Shpacovitch, V. M., Fastrich, M., Cevikbas, F., & Steinhoff, M. S. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01147.x · Cited by 17
Oral small molecules for the treatment of atopic dermatitis: a systematic review
Mobasher, P., Seradj, M. H., Raffi, J., Juhász, M. L. W., & Mesinkovska, N. A. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1544412 · Cited by 16
“Stimulation of the H4R results in Th2 upregulation of IL-31, a cytokine correlated with AD severity [28,29].”
BackgroundDarsow, U. G., Raap, U., & Ständer, S. (2014) · Frontiers in neuroscience · doi:10.1201/b16573-4 · Cited by 16
Self-citationUpasham, S., & Prasad, S. (2021) · ACS Omega · doi:10.1021/acsomega.1c02414 · Cited by 15
Dobrican, C. T., Deleanu, D. M., Muntean, I. A., Pintea, I., Florea, C. M., & Filip, G. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185957 · Cited by 15
“These findings align with previous investigations that have also reported associations between IL-31 serum levels and disease severity in patients suffering from CSU [4], atopic dermatitis [36], and uremic pruritus [37].”
ResultPositive Feedback Cycle of TNFα Promotes Staphylococcal Enterotoxin B-Induced THP-1 Cell Apoptosis
Zhang, X., Shang, W., Yuan, J., Hu, Z., Peng, H., Zhu, J., Hu, Q., Yang, Y., Liu, H., Jiang, B., et al. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00109 · Cited by 15
“…Peng, Junmin Zhu, Qiwen Hu, Yi Yang, Hui Liu, Bei Jiang, Yinan Wang, Shu Li, Xiaomei Hu* and Xiancai Rao* Department of Microbiology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China Staphylococcal enterotoxin B (SEB) has been demonstrated to be of importance…”
BackgroundInfluentialIL-31/33 Axis in Atopic Dermatitis
Łacwik, J., Kraik, K., Laska, J., Tota, M., Sędek, Ł., & Gomułka, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010162 · Cited by 18
“A significant correlation between IL-31 levels and disease severity markers, such as Scoring Atopic Dermatitis (SCORAD) index, and subjectively assessed pruritus intensity has been repeatedly demonstrated [58,59,61].”
IL-31, itch and hematological malignancies
Salvo, E. D., Allegra, A., Casciaro, M., & Gangemi, S. (2021) · Clinical and Molecular Allergy · doi:10.1186/s12948-021-00148-7 · Cited by 15
Lee, S.-H. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.792 · Cited by 14
“There is evidence that IL-31 is up-regulated in atopic dermatitis skin lesions in humans and in skin lesion-induced mice and therefore, IL-31 might present a novel target for anti-inflammatory options in the treatment of atopic dermatitis (34,35).”
McGrath, J. A., Nagy, N., Tanaka, A., & Techanukul, T. (2010) · Acta Dermato Venereologica · doi:10.2340/00015555-0958 · Cited by 14
The pathophysiology of pruritus – A review for clinicians
Brennan, F. P. (2014) · Progress in Palliative Care · doi:10.1179/1743291x14y.0000000110 · Cited by 14
Olopatadine Hydrochloride Decreases Tissue Interleukin-31 Levels in an Atopic Dermatitis Mouse Model
Murota, H., El-latif, M. I. A., Tamura, T., & Katayama, I. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-1648 · Cited by 13
“Recently, interleukin (IE)-31 was found to play a role in pruritus and skin barrier function in AD (3-5).”
BackgroundInnate Immune Regulation of Dermatitis
Abreu, D., & Kim, B. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.04.011 · Cited by 14
TRPV1 Channel in Human Eosinophils: Functional Expression and Inflammatory Modulation
Weihrauch, T., Gray, N., Wiebe, D., Schmelz, M., Limberg, M. M., & Raap, U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031922 · Cited by 12
“Surface expression significantly increased after stimulation with IL-3, IL-31, IL-33, BDNF, NGF-β , TNF-α , and TSLP. IL-31 is already known to upregulate TRPV1 expression in DRG [49], and serum levels correlate with disease severity in AD [53,54].”
BackgroundSelf-citationAllergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients
Nicolàs, L. S. S., Figueras‐Nart, I., García‐Jiménez, I., Bonfill‐Ortí, M., Guilabert, A., Curto‐Barredo, L., Bertolín‐Colilla, M., Ferrán, M., Serra‐Baldrich, E., Pujol, R. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1124018 · Cited by 12
“It is enhanced in the sera from AD patients and correlates with disease severity (4).”
BackgroundPotential diagnostic value of serum/pleural fluid IL-31 levels for tuberculous pleural effusion
Gao, Y., Ou, Q., Wu, J., Zhang, B., Shen, L., Chen, S., Weng, X., Zhang, Y., Zhang, W., & Shao, L. (2016) · Scientific Reports · doi:10.1038/srep20607 · Cited by 12
Immune regulation in pathophysiology and targeted therapy for itch in atopic dermatitis
Lee, C. (2015) · Dermatologica Sinica · doi:10.1016/j.dsi.2015.10.002 · Cited by 12
Tay, C. J., Zhao, X., Allen, J. C., Yew, Y. W., & Tey, H. L. (2021) · Itch · doi:10.1097/itx.0000000000000047 · Cited by 12
“Histamine also triggers the release of interleukin-31, known to be a potent mediator of itch and assists with epidermal barrier function in allergic dermatitis([18,19]).”
BackgroundMechanisms of Itch in Atopic Dermatitis
Kamata, Y., Tominaga, M., & Takamori, K. (2025) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj24-0036-r · Cited by 12
“In particular, IL-31 directly induces pruritus and increases in the lesional skin and serum of AD patients 27-29 ) .”
Interleukin-31 Receptor A Expression in the Dorsal Root Ganglion of Mice with Atopic Dermatitis
Arai, I., & Saitô, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021047 · Cited by 11
“receptors IL-31RA and OSMR are involved in AD, pruritus, and dermatitis at the mRNA level [9,10].”
Background
Metadata
- Authors
- Raap, U., Wichmann, K., Bruder, M., Ständer, S., Wedi, B., Kapp, A., & Werfel, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Münster (DE)
- Corresponding author
- Raap, Ulrike
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 122
- Issue
- 2
- Pages
- 421-423
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2083380164
- Cited by
- 299
- References
- 10
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 15 · 2021: 24 · 2020: 12 · 2019: 17 · 2018: 26 · 2017: 26 · 2016: 26 · 2015: 21 · 2014: 22 · 2013: 12 · 2012: 11
- FWCI
- 15.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Food Allergy and Anaphylaxis Network
- European Commission
- Astellas Pharma
- Medizinischen Hochschule Hannover
- UCB Pharma
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- atopic dermatitis, IL-31, pruritus, disease severity, cytokines, scratching behavior, NC/Nga mice, T cells, quality of life, antipruritic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Humans, Interleukins, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
